EXPRESSION OF ER/PR/HER2, BASAL MARKERS AND ADHESION MOLECULES IN PRIMARY BREAST CANCER AND IN LYMPH NODES METASTASES: A COMPARATIVE IMMUNOHISTOCHEMICAL ANALYSIS

被引:16
|
作者
Adamczyk, Agnieszka [1 ]
Niemiec, Joanna [1 ]
Ambicka, Aleksandra [2 ]
Malecki, Krzysztof [3 ]
Wysocki, Wojciech H. [4 ]
Mitus, Jerzy [4 ]
Rys, Janusz [2 ]
机构
[1] Maria Sklodowska Curie Mem Inst Oncol, Dept Appl Radiobiol, Ctr Oncol, Cracow Branch, PL-31115 Krakow, Poland
[2] Maria Sklodowska Curie Mem Inst Oncol, Dept Tumor Pathol, Ctr Oncol, Cracow Branch, PL-31115 Krakow, Poland
[3] Univ Children Hosp Cracow, Dept Radiotherapy, Krakow, Poland
[4] Maria Sklodowska Curie Mem Inst Oncol, Dept Surg Oncol, Ctr Oncol, Cracow Branch, PL-31115 Krakow, Poland
关键词
primary breast tumour; lymph node metastasis; basal markers; adhesion molecules; IN-SITU HYBRIDIZATION; MATCHED PRIMARY; PRIMARY TUMORS; HER-2; OVEREXPRESSION; MAINTENANCE; PROGRESSION; SIGNATURE; CARCINOMA; THERAPY;
D O I
10.5114/PJP.2012.32769
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The immunophenotypic differences between primary and metastatic tumour cells could influence patient's treatment or/and the results of selected diagnostic procedures. That prompted us to investigate potential differences between primary tumours and corresponding synchronous lymph node metastases in the T >= 1/N + /M0 breast cancer patients. The investigated group consisted of 108 patients with invasive ductal breast cancer, who underwent radical surgery. The expression of ER, PR, HER2 as well as CK5/6, P-cadherin, EGFR and Ep-CAM was assessed immunohistochemically. Our data suggest that ER, PR, HER2, EGFR and CK5/6 are expressed conservatively, with some minor changes between primary tumour and simultaneous lymph node metastases. On the contrary, Ep-CAM and P-cadherin immunoreactivity in primary and metastatic cells varied significantly. This variation might exclude Ep-CAM and P-cadherin as potential diagnostic or therapeutic targets.
引用
收藏
页码:228 / 234
页数:7
相关论文
共 50 条
  • [41] ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
    Isabel Pinhel
    Margaret Hills
    Suzanne Drury
    Janine Salter
    Georges Sumo
    Roger A'Hern
    Judith M Bliss
    Ivana Sestak
    Jack Cuzick
    Peter Barrett-Lee
    Adrian Harris
    Mitch Dowsett
    Breast Cancer Research, 14
  • [42] ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
    Pinhel, Isabel
    Hills, Margaret
    Drury, Suzanne
    Salter, Janine
    Sumo, Georges
    A'Hern, Roger
    Bliss, Judith M.
    Sestak, Ivana
    Cuzick, Jack
    Barrett-Lee, Peter
    Harris, Adrian
    Dowsett, Mitch
    BREAST CANCER RESEARCH, 2012, 14 (02)
  • [43] Immunohistochemical Analysis of ER, PR, Her2 and CK5/6 in Infiltrative Breast Carcinomas in Indian Patients
    Munjal, Kavita
    Ambaye, Abiy
    Evans, Mark F.
    Mitchell, Jeannette
    Nandedkar, Shirish
    Cooper, Kumarasen
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (05) : 773 - 778
  • [44] Change in ER, PR, HER2 status and Ki-67 after primary chemotherapy in breast cancer
    Petit, A.
    Loayza, C.
    Perez Casanova, L.
    Canellas, J.
    Falo, C.
    Perez, J.
    Soler, T.
    Climent, F.
    Gil, M.
    Pernas, S.
    Condom, E.
    VIRCHOWS ARCHIV, 2014, 465 : S124 - S125
  • [45] Comparison of ER, PR, HER2 in primary and paired relapsed/metastatic lesions of metastatic breast cancer patients
    Sari, E.
    Guler, G.
    Hayran, M.
    Altundag, K.
    Gullu, I.
    Ozisik, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Predictive markers in breast cancer: An update on ER and HER2 testing and reporting
    Calhoun, Benjamin C.
    Collins, Laura C.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2015, 32 (05) : 362 - 369
  • [47] Comparative study of immunohistochemical phenotype in primary breast cancer tissues and lymph node metastases
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 123 - 123
  • [48] A Comparative Analysis of the Value of Her2 Immunohistochemistry Scoring in Primary and Metastatic Breast Cancer, in the Era of Her2 "LOW" Breast Cancers
    Bhardwaj, Swati
    Kandel, Avi
    Collins, Victoria
    Zeizafoun, Nebras
    Zeng, Jennifer
    Jaffer, Shabnam
    LABORATORY INVESTIGATION, 2023, 103 (03) : S103 - S103
  • [49] EVALUATION OF HER2/NEU EXPRESSION IN BREAST CANCER BONE METASTASES
    Juan Illarramendi, Jose
    Cordoba, Alicia
    Fernandez Seara, Pilar
    Lopez Cousillas, Alfredo
    Amat, Irene
    Reparaz, Begona
    Ruiz De Azua, Geranie
    De Miguel, Concepcion
    Salgado, Esteban
    Vera, Ruth
    Munoa, Javier
    BREAST, 2011, 20 : S28 - S28
  • [50] HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients
    Wilking, U.
    Skoog, L.
    Elmberger, G.
    Wilking, N.
    Bergh, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)